A blood-brain-barrier penetrant AAV gene therapy rescues neurological deficits in mucolipidosis IV mice.
Sangster, M.; Bishop, M.; Yao, Y.; Feitor, J. F.; Shahriar, S.; Miller, M.; Chekuri, A.; Budnik, B.; Bei, F.; Grishchuk, Y.
Show abstract
Mucolipidosis IV (MLIV) is a rare, autosomal recessive, lysosomal disease characterized by intellectual disability, motor deficits and progressive vision loss. Using AAV9 and AAV-PHP.B as delivery vectors, we previously demonstrated the feasibility of modifying disease course in a mouse model of MLIV by the human MCOLN1 gene transfer. Here, using a primate-enabling capsid AAV.CPP.16 (CPP16), we constructed a new, clinic-oriented MCOLN1 gene expression vector and demonstrated its efficacy in the preclinical model of MLIV. Systemic administration of CPP16-MCOLN1 in adult symptomatic Mcoln1-/- mice at a dose of 1e12 vg per mouse resulted in MCOLN1 expression in the brain and peripheral tissues, alleviated brain pathology, rescued neuromotor function, and completely prevented paralysis. Notable expression of MCOLN1 transcripts was also detected in the retina of the mouse that had exhibited significant degeneration at the time of the treatment. However, no increase of retinal thickness was observed after the gene therapy treatment. Our results suggest a new AAV-based systemic gene replacement therapy for the treatment of MLIV that could be translated into clinical studies.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Gene Therapy Prevents Hepatic Mitochondrial Dysfunction In Murine Deoxyguanosine Kinase Deficiency 94%
- Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: insights into organ toxicities 92%
- Inhibition of cathepsin B blocks amyloidogenesis in the mouse models of neurological lysosomal diseases mucopolysaccharidosis type IIIC and sialidosis 92%
Similar papers in this journal
- AAV-mediated gene therapy for Sialidosis 95%
- Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations 94%
- RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice 94%
Similar papers in this journal
- Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires handling associated with repeated behavioral testing. 93%
- A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature 93%
- Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.